Loading...
Advancing DART Platform Will Drive Targeted Immuno-Oncology Gains Despite Setbacks
n/a
n/a
AnalystHighTarget's Fair Value
n/a
1Y
-68.5%7D
-17.5%1Y
-68.5%7D
-17.5%You can edit this narrative until Aug 10 10:35 PM. Then, changes will post as Updates.